British Hikma announced the start of production of ramdevpir of Gilead, which is currently used for the treatment of patients with COVID-19. A similar agreement for the production of antiretroviral drug Gilead has entered into with Pfizer, writes Reuters.
Ramdevpir is one of two drugs that have confirmed efficacy in the treatment of coronavirus infection in hospitalized patients. Worldwide there is high demand for ramdevpir, forcing Gilead to seek partners for the production of a drug.
In the framework of the agreement, Hikma will adjust the release of ramdevpir in Portugal. As for Pfizer, it intends to make an antiretroviral drug at its plant in Kansas. Financial terms of both deals were not disclosed.